Here's Why You Should Add NuVasive Stock To Your Portfolio

 | Dec 29, 2019 10:17PM ET

NuVasive, Inc. (NASDAQ:NUVA) has been gaining from several sales-building efforts (including product launches), stable sales force and robust segmental growth. The company has also been enhancing focus on international markets. Further, its orthopedic business continues to enjoy a competitive advantage globally on innovative technologies.

Over the past year, shares of the Zacks Rank #2 (Buy) stock have outperformed its industry . The stock has gained 56.6% compared with 16.8% growth of its industry. Also, the company has outperformed the S&P 500’s 27.9% rally during the same period.

The renowned medical device provider, which specializes in developing minimally-disruptive surgical products and procedurally-integrated solutions for spine, has a market capitalization of $4 billion. The company projects 12.9% growth for the next five years and expects to maintain its strong segmental performance. Further, it delivered a positive earnings surprise of 15.1%, on average, over the trailing four quarters.